AI-generated summary
This review evaluated clinical and preclinical studies of transcranial photobiomodulation (near-infrared and red light) for major depressive disorder, identifying 19 studies with original data. The authors report that the treatment appears safe and potentially effective, but that varying treatment parameters across studies complicate firm conclusions about efficacy. They also suggest future trials include biological measures to clarify mechanisms.
- Studies included
- 19
- Who or what was studied
- Patients with major depressive disorder, plus preclinical (animal) models; the abstract does not give a total participant count.
- Limits stated in the abstract
- The abstract states that varying treatment parameters among studies complicate definitive conclusions about efficacy, and that mechanisms require further study.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on journals.lww.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a review: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Oxidative stress, Near-infrared, Transcranial photobiomodulation, Depression. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.